AMAG Pharmaceuticals (AMAG) Shares are Down -1.58%

AMAG Pharmaceuticals (AMAG) : During the past 4 weeks, traders have been relatively bearish on AMAG Pharmaceuticals (AMAG), hence the stock is down -14.47% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -2.07% relative to the S&P 500. The 4-week change in the price of the stock is -14.59% and the stock has fallen -1.58% in the past 1 week.

The stock has recorded a 20-day Moving Average of 4.92% and the 50-Day Moving Average is 6.08%.The 200 Day SMA reached 3.59%. AMAG Pharmaceuticals, Inc. is up 10.41% in the last 3-month period. Year-to-Date the stock performance stands at -21.63%.


AMAG Pharmaceuticals (NASDAQ:AMAG): The stock opened in the green at $23.85 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $23.97 and a low of $23.326 for the day. The stock did not find buyers even at the lows and closed at $23.66 recording a loss of -0.21%. 456,071 shares exchanged hands during the trading day. The stock had closed at $23.71 in the previous days trading.

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on maternal health, anemia and cancer supportive care. The Company markets Makena (hydroxyprogesterone caproate injection), Feraheme (ferumoxytol) Injection for Intravenous (IV) use and MuGard Mucoadhesive Oral Wound Rinse. Feraheme is an IV iron replacement therapy for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is approved for marketing in the United States. Makena is a drug indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds, including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.